Literature DB >> 24293047

Correlates of left ventricular mass in chronic hemodialysis recipients.

Ron Wald1, Marc B Goldstein, Rachel M Wald, Ziv Harel, Anish Kirpalani, Jeffrey Perl, Darren A Yuen, Myles S Wolf, Andrew T Yan.   

Abstract

We aimed to clarify the correlates of left ventricular mass and secondarily, left ventricular volume, in a cohort of prevalent hemodialysis recipients. Left ventricular hypertrophy is common and left ventricular mass is a widely-accepted surrogate for clinical outcomes in dialysis recipients, who are often subjected to chronic pressure and volume overload. However, the precise pathophysiologic mechanisms of left ventricular hypertrophy in this unique population have not been well understood. This was a cross-sectional study of patients receiving conventional thrice-weekly dialysis in Toronto, Canada. Left ventricular mass and volume were assessed with cardiac magnetic resonance and indexed to the patient's height to the power of 2.7. Fibroblast growth factor-23 concentration was measured using a C-terminal enzyme-linked immunosorbent assay. Patient demographics, comorbidities, dialysis-associated blood pressures and ultrafiltration volumes, biochemical and hematologic parameters, vascular access and medications were extracted from clinical records. Multivariable linear regression was used to identify independent correlates of left ventricular mass index (LVMI) and the left ventricular end diastolic volume index (LVEDVI). We enrolled 56 patients, of whom 23 (41.1 %) were women with mean age 54 ± 12 years. Mean LVMI was 31.1 ± 6.8 g/m(2.7). In multivariable analyses, systolic blood pressure and LVEDVI were the only factors significantly associated with LVMI. Post-dialysis weight, percent reduction in urea and the presence of a permanent form of vascular access were associated with LVEDVI. Fibroblast growth factor-23 was not associated with either LVMI or LVEDVI. Blood pressure and left ventricular dilatation are independent determinants of elevated left ventricular mass. Aggressive blood pressure reduction and avoidance of volume overload may confer LVM regression and improve clinical outcomes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24293047     DOI: 10.1007/s10554-013-0337-0

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  35 in total

1.  Echocardiography overestimates left ventricular mass in hemodialysis patients relative to magnetic resonance imaging.

Authors:  G A Stewart; J Foster; M Cowan; E Rooney; T McDonagh; H J Dargie; R S Rodger; A G Jardine
Journal:  Kidney Int       Date:  1999-12       Impact factor: 10.612

Review 2.  A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension.

Authors:  Arnfried U Klingbeil; Markus Schneider; Peter Martus; Franz H Messerli; Roland E Schmieder
Journal:  Am J Med       Date:  2003-07       Impact factor: 4.965

3.  In-center hemodialysis six times per week versus three times per week.

Authors:  Glenn M Chertow; Nathan W Levin; Gerald J Beck; Thomas A Depner; Paul W Eggers; Jennifer J Gassman; Irina Gorodetskaya; Tom Greene; Sam James; Brett Larive; Robert M Lindsay; Ravindra L Mehta; Brent Miller; Daniel B Ornt; Sanjay Rajagopalan; Anjay Rastogi; Michael V Rocco; Brigitte Schiller; Olga Sergeyeva; Gerald Schulman; George O Ting; Mark L Unruh; Robert A Star; Alan S Kliger
Journal:  N Engl J Med       Date:  2010-11-20       Impact factor: 91.245

4.  Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.

Authors:  Tamara Isakova; Huiliang Xie; Wei Yang; Dawei Xie; Amanda Hyre Anderson; Julia Scialla; Patricia Wahl; Orlando M Gutiérrez; Susan Steigerwalt; Jiang He; Stanley Schwartz; Joan Lo; Akinlolu Ojo; James Sondheimer; Chi-yuan Hsu; James Lash; Mary Leonard; John W Kusek; Harold I Feldman; Myles Wolf
Journal:  JAMA       Date:  2011-06-15       Impact factor: 56.272

5.  Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial.

Authors:  Bruce F Culleton; Michael Walsh; Scott W Klarenbach; Garth Mortis; Narine Scott-Douglas; Robert R Quinn; Marcello Tonelli; Sarah Donnelly; Matthias G Friedrich; Andreas Kumar; Houman Mahallati; Brenda R Hemmelgarn; Braden J Manns
Journal:  JAMA       Date:  2007-09-19       Impact factor: 56.272

6.  Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors.

Authors:  J D Harnett; R N Foley; G M Kent; P E Barre; D Murray; P S Parfrey
Journal:  Kidney Int       Date:  1995-03       Impact factor: 10.612

7.  Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.

Authors:  Richard B Devereux; Björn Dahlöf; Eva Gerdts; Kurt Boman; Markku S Nieminen; Vasilios Papademetriou; Jens Rokkedal; Katherine E Harris; Jonathan M Edelman; Kristian Wachtell
Journal:  Circulation       Date:  2004-08-23       Impact factor: 29.690

8.  Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction.

Authors:  H D White; R M Norris; M A Brown; P W Brandt; R M Whitlock; C J Wild
Journal:  Circulation       Date:  1987-07       Impact factor: 29.690

9.  Indexation of left ventricular mass to body surface area and height to allometric power of 2.7: is the difference limited to obese hypertensives?

Authors:  C Cuspidi; S Meani; F Negri; V Giudici; C Valerio; C Sala; A Zanchetti; G Mancia
Journal:  J Hum Hypertens       Date:  2009-03-26       Impact factor: 3.012

10.  Access to kidney transplantation: outcomes of the non-referred.

Authors:  Meteb M Albugami; Romuald Panek; Steven Soroka; Karthik Tennankore; Bryce A Kiberd
Journal:  Transplant Res       Date:  2012-12-10
View more
  9 in total

1.  Bioimpedance analysis versus lung ultrasonography for optimal risk prediction in hemodialysis patients.

Authors:  Dimitrie Siriopol; Luminita Voroneanu; Simona Hogas; Mugurel Apetrii; Angelica Gramaticu; Raluca Dumea; Alexandru Burlacu; Radu Sascau; Mehmet Kanbay; Adrian Covic
Journal:  Int J Cardiovasc Imaging       Date:  2015-10-01       Impact factor: 2.357

Review 2.  Cardiovascular imaging 2014 in the International Journal of Cardiovascular Imaging.

Authors: 
Journal:  Int J Cardiovasc Imaging       Date:  2015-03       Impact factor: 2.357

3.  Association between conversion to in-center nocturnal hemodialysis and right ventricular remodeling.

Authors:  Gauri R Karur; Ron Wald; Marc B Goldstein; Rachel Wald; Laura Jimenez-Juan; Mercedeh Kiaii; Jonathon Leipsic; Anish Kirpalani; Olugbenga Bello; Ashita Barthur; Ming-Yen Ng; Djeven P Deva; Andrew T Yan
Journal:  Nephrol Dial Transplant       Date:  2018-06-01       Impact factor: 5.992

4.  Impact of hemodialysis, left ventricular mass and FGF-23 on myocardial mechanics in end-stage renal disease: a three-dimensional speckle tracking study.

Authors:  Attila Kovács; Mihály Tapolyai; Csilla Celeng; Edit Gara; Mária Faludi; Klára Berta; Astrid Apor; Andrea Nagy; András Tislér; Béla Merkely
Journal:  Int J Cardiovasc Imaging       Date:  2014-07-08       Impact factor: 2.357

Review 5.  Characterizing Cardiac Involvement in Chronic Kidney Disease Using CMR-a Systematic Review.

Authors:  Kenneth Mangion; Kirsty McDowell; Patrick B Mark; Elaine Rutherford
Journal:  Curr Cardiovasc Imaging Rep       Date:  2018-01-31

6.  Determinants of Left Ventricular Characteristics Assessed by Cardiac Magnetic Resonance Imaging and Cardiovascular Biomarkers Related to Kidney Transplantation.

Authors:  G V Ramesh Prasad; Andrew T Yan; Michelle M Nash; S Joseph Kim; Ron Wald; Rachel Wald; Charmaine Lok; Lakshman Gunaratnam; Gauri R Karur; Anish Kirpalani; Philip W Connelly
Journal:  Can J Kidney Health Dis       Date:  2018-11-09

7.  Fibroblast Growth Factor 23 and Risk of New Onset Heart Failure With Preserved or Reduced Ejection Fraction: The PREVEND Study.

Authors:  S Heleen Binnenmars; Georgette E Hoogslag; Stanley M H Yeung; Frank P Brouwers; Stephan J L Bakker; Wiek H van Gilst; Ron T Gansevoort; Gerjan Navis; Adriaan A Voors; Martin H de Borst
Journal:  J Am Heart Assoc       Date:  2022-07-25       Impact factor: 6.106

8.  Quantitative Gadolinium-Free Cardiac Fibrosis Imaging in End Stage Renal Disease Patients Reveals A Longitudinal Correlation with Structural and Functional Decline.

Authors:  Tori A Stromp; Tyler J Spear; Rebecca M Holtkamp; Kristin N Andres; Joshua C Kaine; Wissam H Alghuraibawi; Steve W Leung; Brandon K Fornwalt; Moriel H Vandsburger
Journal:  Sci Rep       Date:  2018-11-19       Impact factor: 4.379

Review 9.  FGF23 in Cardiovascular Disease: Innocent Bystander or Active Mediator?

Authors:  Robert Stöhr; Alexander Schuh; Gunnar H Heine; Vincent Brandenburg
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-27       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.